Annex to the Decision No. 407/10747/2023/1 and to the Certificate of Accreditation No. M-032 dated 27.03.2023.

The Annex is an integral part of the Certificate of Accreditation

Accreditation scope

Name of the accredited subject: **Medirex, a.s.**
Holubyho 35, 902 01 Pezinok
Western Slovakia, Central Laboratory Bratislava
Galvaniho 17/C, 821 04 Bratislava
Western Slovakia, Central Laboratory Nitra
Novozámocká 67, 949 05 Nitra
Eastern Slovakia, Central Laboratory Košice
Magnezitárska 2/C, 040 13 Košice

Laboratory with a fixed accreditation scope.

Item	Object of examination		Established method		Other specification (range, uncertainty, purpose, equipment, etc.)
	Biological material	Analyte / Parameter	Principle	Identification of a method	
1.1	serum	Alanine Aminotransferase (ALT)	photometry	ALT, Lachema (SOP-M 1.1)	IFCC method with pyridoxal-5-phosphate *BA/KE*
1.2		Albumin (ALB)		Albumin, Siemens (SOP-M 1.2)	bromocresol green *BA/KE*
1.3		Alkaline Phosphatase (ALP)		ALP, Lachema (SOP-M 1.3)	IFCC method with AMP *BA/KE*
1.4		α-Amylase (AMS)		AMS, Lachema (SOP-M 1.4)	4,6 -ethyliden-4-nitrophenyl-α-D-maltoheptaoside, IFCC *BA/KE*
1.5		Aspartate Aminotransferase (AST)		AST, Lachema (SOP-M 1.5)	IFCC method with pyridoxal-5-phosphate *BA/KE*
1.6		Bilirubin Total (BILT)		BILT, Lachema (SOP-M 1.6)	method with 2,4-dichloroaniline *BA/KE*
1.7		Total Protein (TP)		TP, Siemens (SOP-M 1.7)	Biuret *BA/KE*
1.8		γ-Glutamyl-transferase (GGT)		GMT, Lachema (SOP-M 1.8)	IFCC method *BA/KE*
1.9		Cholesterol Total (CHOL)		CHOL, Lachema (SOP-M 1.9)	enzymatic CHOD-PAP method *BA/KE*
1.10		Creatine Kinase (CK)		CK, Lachema (SOP-M 1.10)	IFCC method *BA/KE*
1.11		Lactate Dehydrogenase (LDH)		LDH, Lachema (SOP-M 1.11)	IFCC method *BA/KE*
1.12		Triacylglycerols (TAG)		TG, Lachema (SOP-M 1.12)	enzymatic GPO-PAP method *BA/KE*
1.13		Iron (Fe)		IRON_2, Siemens (SOP-M 1.13)	colorimetric method with ferozzine *BA/KE*
1.14	serum, urine	Phosphorus (P)	photometry	IP, Siemens (SOP-M 1.14)	UV method, phosphomolybdate *BA/KE*
1.15		Glucose (GLU)		GLU, Lachema (SOP-M 1.15)	enzymatic GOD-PAP method *BA/KE*
1.16		Magnesium (Mg)		MG, Siemens (SOP-M 1.16)	colorimetric method with xylidyl blue *BA/KE*
1.17		Creatinine (CREA)		Creatinine, Dialab (SOP-M 1.17)	modified Jaffe method with compensation *BA/KE*

Annex to the Decision No. 407/10747/2023/1 and to the Certificate of Accreditation No. M-032 dated 27.03.2023.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specification (range, uncertainty, purpose, equipment, etc.)
	Biological material	Analyte / Parameter	Principle	Identification of a method	
1.18	serum, urine	Uric Acid (UA)	photometry	UA, Lachema (SOP-M 1.18)	enzymatic method uricase-PAP *BA/KE*
1.19		Urea (UREA)		UREA, Lachema (SOP-M 1.19)	enzymatic UV method urease-GLDH *BA/KE*
1.20		Calcium (Ca)		CA, Siemens (SOP-M 1.20)	colorimetric method with o-cresolphtalein complexone *BA/KE*
1.21		Chloride (Cl)	potentiometry	Chloride, Siemens (SOP-M 1.21)	ISE with dilution *BA/KE*
1.22		Potassium (K)		Potassium, Siemens (SOP-M 1.22)	ISE with dilution *BA/KE*
1.23		Sodium (Na)		Sodium, Siemens (SOP-M 1.23)	ISE with dilution *BA/KE*
1.24	serum	C-Reactive Protein (CRP)	immunoturbidimetry	CRP, DiaSys (SOP-M 1.24)	*BA/KE*
1.25		Immunoglobulin A (IgA)		IgA, DiaSys (SOP-M 1.25)	*BA/KE*
1.26		Immunoglobulin G (IgG)		IgG, DiaSys (SOP-M 1.26)	*BA/KE*
1.27		Immunoglobulin M (IgM)		IgM, DiaSys (SOP-M 1.27)	*BA/KE*
1.28		Transferrin (Trf)		TRF, Siemens (SOP-M 1.28)	*BA/KE/NR*
2.1		α-Fetoprotein (AFP)	electrochemi – luminiscence immunoassay	AFP cobas, Roche (SOP-M 2.1)	*BA/KE*
2.2		Procollagen-type 1 N-terminal propeptide (P1NP)		total P1NP cobas, Roche (SOP-M 2.2)	*BA/KE*
2.3		β – Isomerized C – terminal telopeptides of type I collagen (CTx)		β - CrossLaps/ serum cobas, Roche (SOP-M 2.3)	*BA/KE*
2.4	unoccupied				
2.5	serum	17β-Estradiol (E2)	electrochemi – luminiscence immunoassay	Estradiol III cobas, Roche (SOP-M 2.5)	*BA/KE*
2.6		Follicle stimulating hormone (FSH)		FSH cobas, Roche (SOP-M 2.6)	*BA/KE*
2.7		Choriogonado-tropin (hCG)		HCG+β cobas, Roche (SOP-M 2.7)	*BA/KE*
2.8		Immunoglobulin E (IgE)	chemiluminiscence immunoassay	IgE Advia Centaur, Siemens (SOP-M 2.8)	*BA/KE*
2.9	unoccupied				
2.10	serum	Luteinizing hormone (LH)	electrochemi – luminiscence immunoassay	LH cobas, Roche (SOP-M 2.10)	*BA/KE*
2.11	unoccupied				

Annex to the Decision No. 407/10747/2023/1 and to the Certificate of Accreditation No. M-032 dated 27.03.2023.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specification (range, uncertainty, purpose, equipment, etc.)
	Biological material	Analyte / Parameter	Principle	Identification of a method	
2.12	serum	Pregnancy-associated plasma protein A (PAPP-A)	electrochemi – luminiscence immunoassay	PAPP-A cobas, Roche (SOP-M 2.12)	*BA/KE*
2.13		Parathyroid hormone intact (PTH)		PTH cobas, Roche (SOP-M 2.13)	*BA/KE*
2.14		Progesterone (PROG)		Progesterone III cobas, Roche (SOP-M 2.14)	*BA/KE*
2.15		Testosterone (TST)		Testosterone II cobas, Roche (SOP-M 2.15)	*BA/KE*
2.16		Troponin T cardiac – high sensitive (hs cTnT)		Troponin T hs, STAT cobas, Roche (SOP-M 2.16)	*BA/KE*
2.17		Ferritin (FER)	chemiluminiscence immunoassay	FER Advia Centaur, Siemens (SOP-M 2.17)	*BA/KE*
2.18		Prostate-specific antigen (tPSA)		PSA Advia Centaur, Siemens (SOP-M 2.18)	*BA/KE*
2.19		Prostate-specific antigen free (fPSA)		fPSA Advia Centaur, Siemens (SOP-M 2.19)	*BA/KE*
2.20		Thyrotropin (TSH)	electrochemi – luminiscence immunoassay	TSH cobas, Roche (SOP-M 2.20)	*BA/KE*
2.21		Triiodothyronine free (fT3)		FT3 III cobas, Roche (SOP-M 2.21)	*BA/KE*
2.22		Thyroxine free (fT4)		FT4 III cobas, Roche (SOP-M 2.22)	*BA/KE*
3.1		Protein electrophoresis (ELFO)	agarose gel electrophoresis	Hydragel 54 β1-β2, Sebia (SOP-M 3.1)	*BA/KE*
3.2	serum, urine	Monoclonal proteins (IF)	agarose gel electrophoresis and immunofixation	Hydragel 4 IF, Hydragel 4 Urine Profil, Sebia (SOP-M 3.2)	qualitative method *BA/KE*
3.3	unoccupied				
3.4	peripheral blood	Glycated haemoglobin A1c (HbA1c)	HPLC	Variant II Turbo, D-100, BioRad (SOP-M 3.4)	ionex HPLC method *BA/KE/NR*

Annex to the Decision No. 407/10747/2023/1 and to the Certificate of Accreditation No. M-032 dated 27.03.2023.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specification (range, uncertainty, purpose, equipment, etc.)
	Biological material	Analyte / Parameter	Principle	Identification of a method	
4.1	peripheral blood	*Blood cell count with differential:*		BC-6800, BC-6200, BC-6000 Auto Hematology Analyzer, Mindray (SOP-M 4.1)	*BA/KE/NR*
		Hemoglobin (HGB)	photometry		
		Erythrocytes (RBC)	electrical impedance		
		Platelets (PLT)			
		Leukocytes (WBC)	flow cytometry		
		Neutrophils granulocytes (NEU)			
		Lymphocytes (LYM)			
		Monocytes (MONO)			
		Eosinophils granulocytes (EOS)			
		Basophils granulocytes (BASO)			
4.2	plasma	Prothrombin time (PT)	coagulation assay	Thromborel S, Siemens (SOP-M 4.2)	*BA/KE/NR*
4.3	unoccupied				
4.4	plasma	Fibrinogen (FBG)	coagulation assay	Dade Thrombin Reagent, Siemens (SOP-M 4.4)	*BA/KE/NR*
4.5		Antithrombin III (AT III)	chromogenic assay	Berichrom Antithrombin III, Siemens (SOP-M 4.5)	*BA/KE*
4.6		D-dimer	immuno-turbidimetric assay	INNOVANCE D-Dimer, Siemens (SOP-M 4.6)	*BA/KE/NR*
5.1	peripheral blood	CD3+	flow cytometry	Navios Flow Cytometer, Monoclonal Antibodies, Beckman Coulter (SOP-M 5.1)	*BA/KE/NR*
		CD3+CD4+			
		CD3+CD8+			
		NK cells			
		B lymphocytes			
5.2	serum	Specific IgE	fluorescence immunoassay	ImmunoCAP 250, ImmunoCAP 1000, Phadia, Specific IgE (SOP-M 5.2)	investigated allergens according to the manufacturer's offer of the mentioned measuring systems *BA/KE*
6.1	peripheral blood, bone marrow	Fusion genes (BCR-ABL)	Real Time PCR	Reference 6.1 (SOP-M 6.1)	RTQ-PCR reverse quantitative method *BA*
6.2	peripheral blood, bone marrow	V617F mutation of JAK2 gene	Real Time PCR	Reference 6.2 (SOP-M 6.2)	qualitative method RQ PCR alelic discrimination *BA*
6.3	peripheral blood, bone marrow, amniotic fluid	Molecular - cytogenetic analysis	FISH fluorescent in situ hybridization	Reference 6.3 (SOP-M 6.3)	qualitative method *BA*

Annex to the Decision No. 407/10747/2023/1 and to the Certificate of Accreditation No. M-032 dated 27.03.2023.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specification (range, uncertainty, purpose, equipment, etc.)
	Biological material	Analyte / Parameter	Principle	Identification of a method	
6.4	peripheral blood	Karyotyping of chromosomes	Cytogenetic analysis of chromosomes after 72 hours peripheral blood cultivation	Reference 6.4 (SOP-M 6.4)	qualitative method *BA*
6.5	amniotic fluid	Chromosome aneuploidy 13,18,21,X and Y	PCR/fluorescent PCR	Reference 6.5 (SOP-M 6.5)	qualitative method QF PCR *BA*
7.1	serum, plasma	Hepatitis B virus surface antigen (HBsAg)	electrochemi – luminiscence immunoassay	HBsAg II cobas, Roche (SOP-M 7.1)	qualitative method *BA/KE*
7.2		(anti-HBs)		Anti-HBs II cobas, Roche (SOP-M 7.2)	*BA*
7.3		(anti-HBc IgM)		Anti-HBc IgM cobas, Roche (SOP-M 7.3)	qualitative method *BA*
7.4		(anti-HBc total)		Anti-HBc total cobas, Roche (SOP-M 7.4)	qualitative method *BA*
7.5		Hepatitis B virus e antigen (HBeAg)		HBeAg cobas, Roche (SOP-M 7.5)	qualitative method *BA*
7.6		Hepatitis B virus e antibodies (anti-HBe)		Anti-HBe cobas, Roche (SOP-M 7.6)	qualitative method *BA*
7.7	serum, plasma	Hepatitis C virus antibodies (anti-HCV)	electrochemi – luminiscence immunoassay	Anti-HCV II cobas, Roche (SOP-M 7.7)	qualitative method *BA/KE*
7.8		Human immunodeficiency virus antigen and antibodies (HIV Ag/Ab)		HIV Combi PT, HIV duo cobas, Roche (SOP-M 7.8)	qualitative method *BA/KE*
7.9		Hepatitis B virus DNA (HBV DNA)	Real Time PCR	HBV cobas, Roche (SOP-M 7.9)	*BA*
7.10		Hepatitis C virus RNA (HCV RNA)	Real Time PCR	HCV cobas, Roche (SOP-M 7.10)	Real Time RT PCR *BA*
8.1	blood culture	The presence of diagnostically significant microorganisms	cultivation	Reference 8.1 (SOP-M 8.1)	qualitative method *BA/KE/NR*
8.2	body fluid cultures (excluding blood, cerebrospinal fluid and urine)	The presence of diagnostically significant microorganisms		Reference 8.2 (SOP-M 8.2)	qualitative method *BA/KE/NR*
8.3	catheter tip cultures	The presence of diagnostically significant microorganisms		Reference 8.3 (SOP-M 8.3)	qualitative method *BA/KE*
8.4	cerebrospinal fluid	The presence of diagnostically significant microorganisms		Reference 8.4 (SOP-M 8.4)	qualitative method *BA/KE*

Annex to the Decision No. 407/10747/2023/1 and to the Certificate of Accreditation No. M-032 dated 27.03.2023.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specification (range, uncertainty, purpose, equipment, etc.)
	Biological material	Analyte / Parameter	Principle	Identification of a method	
8.5	fecal and other gastrointesti-nal specimens	The presence of diagnostically significant microorganisms	cultivation	Reference 8.5 (SOP-M 8.5)	qualitative method *BA/KE/NR*
8.6	specimens from genital tract	The presence of diagnostically significant microorganisms		Reference 8.6 (SOP-M 8.6)	qualitative method *BA/KE/NR*
8.7	human biological material (wound, ocular and otitis cultures)	The presence of diagnostically significant microorganisms		Reference 8.7 (SOP-M 8.7)	qualitative method *BA/KE/NR*
8.8	specimens from respiratory tract	The presence of diagnostically significant microorganisms		Reference 8.8 (SOP-M 8.8)	qualitative method *BA/KE/NR*
8.9	urine	The presence of diagnostically significant microorganisms		Reference 8.9 (SOP-M 8.9)	qualitative method *BA/KE/NR*
8.10	culture of microorga-nisms	Identification of microorganisms	mass spectrometry	Reference 8.10 (SOP-M 8.10)	qualitative method *BA/KE*
8.11	human biological material and culture of microorga-nisms	The presence of microorganisms, cellular elements and identification of microorganisms	microscopic examination/staining procedures	Reference 8.11 (SOP-M 8.11)	qualitative method *BA/KE/NR*
8.12	culture of microorga-nisms	Identification of aerobic, fakultative anaerobic, microaerophilic and anaerobic bacteria	conventional biochemical tests, growth properties and antigen characteristic	Reference 8.12 (SOP-M 8.12)	qualitative method *BA/KE/NR*
8.13	culture of microorga-nisms	Growth and/or inhibition growth in the presence of antimicrobial agents	antimicrobial susceptibility testing (disc diffusion and microdilution method, MIC)	Reference 8.13 (SOP-M 8.13)	qualitative method *BA/KE/NR*
8.14	biological indicators for monitoring efficacy of sterilization processes	Grow of microorganism – biological indicator	cultivation	Reference 8.14 (SOP-M 8.14)	qualitative method *BA/KE/NR*
9.1	human biological material	The presence of microscopic fungi		Reference 9.1 (SOP-M 9.1)	qualitative method *BA*
9.2		The presence of microscopic fungi and cell elements	microscopic examination	Reference 9.2 (SOP-M 9.2)	qualitative method *BA*
9.3	cultures of microscopic fungi	Micromorphologic al features of microscopic fungi		Reference 9.3 (SOP-M 9.3)	qualitative method *BA*

Annex to the Decision No. 407/10747/2023/1 and to the Certificate of Accreditation No. M-032 dated 27.03.2023.

The Annex is an integral part of the Certificate of Accreditation

Item	Object of examination		Established method		Other specification (range, uncertainty, purpose, equipment, etc.)
	Biological material	Analyte / Parameter	Principle	Identification of a method	
9.4	cultures of microscopic fungi	Growth of microscopic fungi in presence specific substance and temperature	analysis of metabolic and growth features	Reference 9.4 (SOP-M 9.4)	qualitative method *BA*
10.1	serum, plasma	IgM antibodies against *Toxoplasma gondii*	electrochemi – luminiscence immunoassay	Elecsys Toxo IgM cobas, Roche (SOP-M 10.1)	qualitative method *BA*
10.2		IgG antibodies against *Toxoplasma gondii*		Elecsys Toxo IgG cobas, Roche (SOP-M 10.2)	*BA*
10.3		Avidity of IgG antibodies against *Toxoplasma gondii*		Elecsys Toxo IgG Avidity cobas, Roche (SOP-M 10.3)	qualitative method *BA*
10.4	stool	The presence of helminth eggs and protozoan cysts	microscopy	Reference 10.4 (SOP-M 10.4)	qualitative method *BA*
10.5	perianal tape test	The presence of *Enterobius vermicularis*	microscopy	Reference 10.5 (SOP-M 10.5)	qualitative method *BA*

NOTES:

OP-M - Standard Operating Procedure for Method
BA - examination is done in Medirex, a.s. Western Slovakia, Central Laboratory Bratislava
KE - examination is done in Medirex, a.s. Eastern Slovakia, Central Laboratory Košice
NR - examination is done in Medirex, a.s. Western Slovakia, Central Laboratory Nitra

References:

6.1 FusionQuant Kits for Real-time Quantitative PCR Analysis of Fusion Gene Transcripts, Ipsogen, Cancer profiler, Instructions for use, 2009
https://www.qiagen.com/us/shop/detection-solutions/personalized-healthcare/ipsogen-bcr-abl 1-mbcr-is-mmr kits/#orderinginformation
Tempus TM Spin RNA Isolation Kit (kat. č. 4380204), (Life technologies)
https://tools.lifetechnologies.com/content/sfs/brochures/cms_057271.pdf
www.implen.co.uk/product.php5?id=100
Cross N. C., White H. E. et al. (2015): Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. Leukemia. 2015 May; 29(5): 999-1003
Gabert J., Beillard E. et al. (2003): Standardization and quality control studies od ´real-time´ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003 Dec; 17(12):2318-57
6.2 "Ipsogen JAK2 MutaScreen Handbook": catalog no. 673013, QIAGEN GmbH, QIAGEN Strasse 1, 40724 Hilden, GERMANY, January 2013, www.qiagen.com
Magnesia 16, automated Nucleic Acid Extractor (Anatolia genexorks, www.anatoliagenetics.com)
6.3 ISCN (2016): An International System for Human Cytogenetic Nomenclature (2016).
McGowan-Jordan J., Simons A., Schmid M.; Karger, Basel 2016
http://www.metasystems-international.com
http://www.eurogentest.org/index.php?id=699
http://www.e-c-a.eu/files/downloads/Guidelines/NL31_Acquired_Guidelines.pdf
http://www.molecular.abbott/int/en/vysis-fish-chromosome-search
www.kreatech.com
www.zytovision.com
www.cytocell.com/probe
6.4. www.e-c-a.eu/en/
www.metasystems-international.com
www.acgs.uk.com
ISCN (2013): An International System for Human Genetic Nomenclature. Shaffer L. G., McGowan-Jordan J., Schmid M.

(eds); S. Karger, Basel. 2013
Analyzing Chromosomes, Czepulkowski B.; BIOS Scientific Publishers Limitid, 2001
6.5 Návod k použití, Devyser Complete v2. CE-IVD, 7-A022-CZ, v2-2012
ISCN (2016): An International System for Human Cytogenetic Nomenclature (2016). McGowan-Jordan J., Simons A., Schmid M.; Karger, Basel 2016
8.1 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.4, 4
8.2 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.5, 4
8.3 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.6, 4
8.4 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.7, 4
8.5 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.8
8.6 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.9, 4
8.7 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.10, 3.13, 3.11.5
8.8 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.11
8.9 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.12
8.10 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 3, kap. 12.5
8.11 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.2
8.12 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 1, kap. 3.16, 3.17, 3.18, 4
8.13 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2, kap. 5
8.14 Vyhláška MZ SR č. 553/2007
9.1 Jorgensen et al.: Manual of Clinical Microbiology, 11 Ed., 2015, Vol. 2., sekcia VI, kap. 114, 115, s. 1944-1964; Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2, kap. 8.2, 8.4, 8.5
9.2 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2., kap. 8.3, podkap. 8.3.1.1 - 8.3.1.9
Jorgensen et al.: Manual of Clinical Microbiology,11 Ed., 2015, Vol. 2, sekcia VI, kap. 116, str. 1965-1969
9.3 Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2., kap. 8.5, 8.6, 8.7, 8.9
9.4 Kurtzman et al.: Manual of Clinical Microbiology, 5 Ed., 2011, Vol. 1., kap. 7, s. 100-107
Leber et al.: Clinical Microbiology Procedures Handbook, 4 Ed., 2016, Vol. 2, kap. 8.7, 8.8, 8.9
10.4 Ondriska, F., Boldiš, V., Garajová, M., Mrva, M.: Klinická parazitológia 1. vyd., 2016, kap. 10.1, 10.2, s. 227-229
10.5 Ondriska, F., Boldiš, V., Garajová, M., Mrva, M.: Klinická parazitológia 1. vyd., 2016, kap. 9.1.2, s. 221-222

***

SLOVENSKÁ NÁRODNÁ AKREDITAČNÁ SLUŽBA
SNAS